Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

3 years ago

BETHESDA, Md., March 09, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company…

Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Barclays Global Healthcare Conference March 14, 2023

3 years ago

MORRISTOWN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development…

Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year 2023 Results on May 25, 2023

3 years ago

LAKEWOOD, Colo., March 09, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results…

Hydreight Technologies Inc. Announces DTC Eligibility

3 years ago

VANCOUVER, British Columbia and LAS VEGAS, March 09, 2023 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV:NURS) (FSE: SO6) (OTCQB: HYDTF)…

Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

3 years ago

-- Announced preclinical data providing further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function, as well as…

Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023

3 years ago

ATLANTA, March 09, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide…

Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting

3 years ago

Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national…

Novel Target-Specific Nanoparticles for Diagnosis and Treatment of Pancreatic Cancer

3 years ago

By Dr. Jill Smith Pancreatic cancer is well known as one of the deadliest cancers, with a paltry 11% survival…

Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer

3 years ago

Marcin Szumowski Chief Executive Officer Samson Fung Chief Medical Officer OATD-02 First-in-class dual arginase inhibitorMolecure announces first patient dosed in…

Smile Health Orthodontics (SHO) Now Offering Patients 3D Printed Clear Aligners & 3D Printed LightForce Ceramic Braces

3 years ago

Patients can safely and comfortably accelerate their treatment compared to traditional metal braces A 3D printed model fresh out of…